The activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Activist investor Starboard Value said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose the drug-maker's acquisition of Celgene.
Smith argued that Starboard was"surprised" to hear of the proposed acquisition on the heels of what he characterized as poor financial and stock price performance over the last few years.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition
Weiterlesen »
Top Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
Weiterlesen »
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
Weiterlesen »
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition
Weiterlesen »
Top Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
Weiterlesen »
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
Weiterlesen »
Value investor Greenblatt says market in expensive range historically, likes Home Depot, Boeing
Weiterlesen »